Skip to main content
Premium Trial:

Request an Annual Quote

Xoma and Diversa Sign Antibody License and Development Agreement

NEW YORK, Jan. 6 (GenomeWeb News) - Xoma of Berkeley, Calif., and Diversa of San Diego have signed a licensing and development agreement, the companies said today.


Diversa will license Xoma's antibody expression technology as well as obtain an option for an antibody production license. In return, Xoma will receive a license fee and potential future milestone and royalty payments.


Xoma and Diversa also plan to co-develop antibodies for autoimmune-related diseases. Xoma will provide Diversa with research funding, and Diversa will be entitled to milestone and royalty payments on any drugs developed under the agreement.


The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.